Institutional investors purchased a net $855.9 thousand shares of GENT during the quarter ended March 2013. This may signal that the smart money is gaining interest in this company as the 45.78% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Mutual fund holders | 42.46% |
| Other institutional | 3.32% |
| Individual stakeholders | -- |